22 May 2013
Keywords: celltech, merck, co, extend, pde4, collaboration, drug
Article | 29 September 2003
US drug major Merck & Co has exercised its option to extend the development period regarding its phosphodiesterase-4 (PDE4) inhibitors
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
29 September 2003
21 May 2013
© 2013 thepharmaletter.com